AAPL333.08+0.81 (+0.24%) ▲|ABBV261.77+4.65 (+1.81%) ▲|ABT103.09+1.14 (+1.12%) ▲|ACN195.00+11.10 (+6.04%) ▲|ADBE265.60+13.37 (+5.30%) ▲|AMAT424.21-32.28 (-7.07%) ▼|AMD493.41-22.72 (-4.40%) ▼|AMGN381.50+4.15 (+1.10%) ▲|AMT176.94-0.91 (-0.51%) ▼|AMZN253.54-3.24 (-1.26%) ▼|AVGO344.72-17.27 (-4.77%) ▼|AXP327.78+3.09 (+0.95%) ▲|BA210.27-0.18 (-0.09%) ▼|BAC59.47-3.22 (-5.14%) ▼|BKNG175.35+1.43 (+0.82%) ▲|BLK1,065.60-14.05 (-1.30%) ▼|BMY64.10+0.46 (+0.72%) ▲|BNY157.66-5.00 (-3.07%) ▼|BRK-B514.95+4.58 (+0.90%) ▲|C136.18-2.64 (-1.90%) ▼|CAT784.00-34.57 (-4.22%) ▼|CL87.89+1.09 (+1.26%) ▲|CMCSA24.88-0.32 (-1.27%) ▼|COF206.68-1.62 (-0.78%) ▼|COP136.67-0.68 (-0.50%) ▼|COST918.91+14.14 (+1.56%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.06-2.07 (-1.85%) ▼|CVS95.55+0.89 (+0.94%) ▲|CVX212.17-1.89 (-0.88%) ▼|DE681.46+5.72 (+0.85%) ▲|DHR203.25+3.11 (+1.55%) ▲|DIS108.59+2.04 (+1.91%) ▲|DUK119.02-0.40 (-0.34%) ▼|EMR148.30-3.89 (-2.56%) ▼|FDX312.57+1.80 (+0.58%) ▲|GD356.81+0.91 (+0.26%) ▲|GE317.56-6.10 (-1.88%) ▼|GEV874.76-82.51 (-8.62%) ▼|GILD146.41+2.69 (+1.87%) ▲|GM87.16+1.54 (+1.80%) ▲|GOOG345.71+10.26 (+3.06%) ▲|GOOGL349.39+10.89 (+3.22%) ▲|GS988.45-40.73 (-3.96%) ▼|HD310.87+2.13 (+0.69%) ▲|HON201.38-0.98 (-0.48%) ▼|IBM249.09+5.80 (+2.38%) ▲|INTC97.19-5.75 (-5.59%) ▼|INTU339.15+17.58 (+5.47%) ▲|ISRG377.94+8.79 (+2.38%) ▲|JNJ266.32+0.74 (+0.28%) ▲|JPM350.13-6.10 (-1.71%) ▼|KO89.35+1.06 (+1.20%) ▲|LIN464.41-1.81 (-0.39%) ▼|LLY1,138.28+22.58 (+2.02%) ▲|LMT529.38+5.19 (+0.99%) ▲|LOW198.17+1.35 (+0.69%) ▲|LRCX273.49-24.73 (-8.29%) ▼|MA574.42+5.23 (+0.92%) ▲|MCD257.49+4.96 (+1.96%) ▲|MDLZ62.39-0.05 (-0.08%) ▼|MDT93.80+2.84 (+3.12%) ▲|META665.60+17.57 (+2.71%) ▲|MMM162.02-2.95 (-1.79%) ▼|MO70.61+1.63 (+2.36%) ▲|MRK144.85+0.92 (+0.64%) ▲|MS206.58-7.80 (-3.64%) ▼|MSFT505.41+9.78 (+1.97%) ▲|MU924.03-51.23 (-5.25%) ▼|NEE81.63-0.68 (-0.83%) ▼|NFLX80.32+2.92 (+3.77%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.35+9.82 (+7.41%) ▲|NVDA210.96-7.33 (-3.36%) ▼|ORCL144.79-5.49 (-3.65%) ▼|PEP136.34+0.02 (+0.01%) ▲|PFE27.72+0.00 (+0.00%) ▲|PG146.13+0.86 (+0.59%) ▲|PLTR173.31+6.08 (+3.64%) ▲|PM194.86+3.80 (+1.99%) ▲|QCOM180.15-1.82 (-1.00%) ▼|RTX195.34-2.34 (-1.18%) ▼|SBUX99.07+0.33 (+0.33%) ▲|SCHW107.31+0.06 (+0.06%) ▲|SO87.00-0.17 (-0.20%) ▼|SPG204.97+0.14 (+0.07%) ▲|T26.51+0.45 (+1.73%) ▲|TMO613.62+3.80 (+0.62%) ▲|TMUS182.90+0.57 (+0.31%) ▲|TSLA358.97-6.47 (-1.77%) ▼|TXN263.42-5.28 (-1.97%) ▼|UBER72.63+0.96 (+1.34%) ▲|UNH383.55+6.78 (+1.80%) ▲|UNP285.08+0.68 (+0.24%) ▲|UPS102.46+2.18 (+2.17%) ▲|USB62.68-0.16 (-0.25%) ▼|V375.28+4.83 (+1.30%) ▲|VZ51.29+0.68 (+1.34%) ▲|WFC88.71-1.58 (-1.75%) ▼|WMT109.08+1.93 (+1.80%) ▲|XOM165.08-0.91 (-0.55%) ▼|AAPL333.08+0.81 (+0.24%) ▲|ABBV261.77+4.65 (+1.81%) ▲|ABT103.09+1.14 (+1.12%) ▲|ACN195.00+11.10 (+6.04%) ▲|ADBE265.60+13.37 (+5.30%) ▲|AMAT424.21-32.28 (-7.07%) ▼|AMD493.41-22.72 (-4.40%) ▼|AMGN381.50+4.15 (+1.10%) ▲|AMT176.94-0.91 (-0.51%) ▼|AMZN253.54-3.24 (-1.26%) ▼|AVGO344.72-17.27 (-4.77%) ▼|AXP327.78+3.09 (+0.95%) ▲|BA210.27-0.18 (-0.09%) ▼|BAC59.47-3.22 (-5.14%) ▼|BKNG175.35+1.43 (+0.82%) ▲|BLK1,065.60-14.05 (-1.30%) ▼|BMY64.10+0.46 (+0.72%) ▲|BNY157.66-5.00 (-3.07%) ▼|BRK-B514.95+4.58 (+0.90%) ▲|C136.18-2.64 (-1.90%) ▼|CAT784.00-34.57 (-4.22%) ▼|CL87.89+1.09 (+1.26%) ▲|CMCSA24.88-0.32 (-1.27%) ▼|COF206.68-1.62 (-0.78%) ▼|COP136.67-0.68 (-0.50%) ▼|COST918.91+14.14 (+1.56%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.06-2.07 (-1.85%) ▼|CVS95.55+0.89 (+0.94%) ▲|CVX212.17-1.89 (-0.88%) ▼|DE681.46+5.72 (+0.85%) ▲|DHR203.25+3.11 (+1.55%) ▲|DIS108.59+2.04 (+1.91%) ▲|DUK119.02-0.40 (-0.34%) ▼|EMR148.30-3.89 (-2.56%) ▼|FDX312.57+1.80 (+0.58%) ▲|GD356.81+0.91 (+0.26%) ▲|GE317.56-6.10 (-1.88%) ▼|GEV874.76-82.51 (-8.62%) ▼|GILD146.41+2.69 (+1.87%) ▲|GM87.16+1.54 (+1.80%) ▲|GOOG345.71+10.26 (+3.06%) ▲|GOOGL349.39+10.89 (+3.22%) ▲|GS988.45-40.73 (-3.96%) ▼|HD310.87+2.13 (+0.69%) ▲|HON201.38-0.98 (-0.48%) ▼|IBM249.09+5.80 (+2.38%) ▲|INTC97.19-5.75 (-5.59%) ▼|INTU339.15+17.58 (+5.47%) ▲|ISRG377.94+8.79 (+2.38%) ▲|JNJ266.32+0.74 (+0.28%) ▲|JPM350.13-6.10 (-1.71%) ▼|KO89.35+1.06 (+1.20%) ▲|LIN464.41-1.81 (-0.39%) ▼|LLY1,138.28+22.58 (+2.02%) ▲|LMT529.38+5.19 (+0.99%) ▲|LOW198.17+1.35 (+0.69%) ▲|LRCX273.49-24.73 (-8.29%) ▼|MA574.42+5.23 (+0.92%) ▲|MCD257.49+4.96 (+1.96%) ▲|MDLZ62.39-0.05 (-0.08%) ▼|MDT93.80+2.84 (+3.12%) ▲|META665.60+17.57 (+2.71%) ▲|MMM162.02-2.95 (-1.79%) ▼|MO70.61+1.63 (+2.36%) ▲|MRK144.85+0.92 (+0.64%) ▲|MS206.58-7.80 (-3.64%) ▼|MSFT505.41+9.78 (+1.97%) ▲|MU924.03-51.23 (-5.25%) ▼|NEE81.63-0.68 (-0.83%) ▼|NFLX80.32+2.92 (+3.77%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.35+9.82 (+7.41%) ▲|NVDA210.96-7.33 (-3.36%) ▼|ORCL144.79-5.49 (-3.65%) ▼|PEP136.34+0.02 (+0.01%) ▲|PFE27.72+0.00 (+0.00%) ▲|PG146.13+0.86 (+0.59%) ▲|PLTR173.31+6.08 (+3.64%) ▲|PM194.86+3.80 (+1.99%) ▲|QCOM180.15-1.82 (-1.00%) ▼|RTX195.34-2.34 (-1.18%) ▼|SBUX99.07+0.33 (+0.33%) ▲|SCHW107.31+0.06 (+0.06%) ▲|SO87.00-0.17 (-0.20%) ▼|SPG204.97+0.14 (+0.07%) ▲|T26.51+0.45 (+1.73%) ▲|TMO613.62+3.80 (+0.62%) ▲|TMUS182.90+0.57 (+0.31%) ▲|TSLA358.97-6.47 (-1.77%) ▼|TXN263.42-5.28 (-1.97%) ▼|UBER72.63+0.96 (+1.34%) ▲|UNH383.55+6.78 (+1.80%) ▲|UNP285.08+0.68 (+0.24%) ▲|UPS102.46+2.18 (+2.17%) ▲|USB62.68-0.16 (-0.25%) ▼|V375.28+4.83 (+1.30%) ▲|VZ51.29+0.68 (+1.34%) ▲|WFC88.71-1.58 (-1.75%) ▼|WMT109.08+1.93 (+1.80%) ▲|XOM165.08-0.91 (-0.55%) ▼|
18.5 C
New York
Tuesday, September 15, 2026

Tag: collaboration

newssourceFORcompanyinformationcontent1releasesmarket

The Week in Canadian Press Releases: 10 Stories You Need to See

A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, June 6, 2025 /CNW/ - With thousands of press releases published...

May in Review: 14 Top Health Press Releases

A roundup of the most newsworthy healthcare press releases from PR Newswire, including Sanofi's $20B investment, Novo Nordisk's new initiatives for Wegovy® and positive topline...

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World’s First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions...

AKEEGA® (niraparib e abiraterone acetato): la compressa a doppia azione di Johnson & Johnson è la prima combinazione di PARP inibitori a mostrare una...

I risultati dello studio di Fase 3 AMPLITUDE mettono in luce il potenziale di niraparib e abiraterone acetato nel ritardare la progressione del cancro e il peggioramento dei sintomi1

Axi Showcases Their Capital Allocation Program, Axi Select, at the Finance Magnates Africa Summit

SYDNEY, June 06, 2025 (GLOBE NEWSWIRE) -- Leading online FX and CFD broker Axi attended the Finance Magnates Africa Summit (FMAS:25), held on May 29-30, 2025, at the Cape Town International Convention Centre in Cape Town, South Africa.

Pony.ai Accelerates Gen-7 Robotaxi Deployment with Road Testing Launch in China’s Guangdong

GUANGZHOU, China, June 6, 2025 /PRNewswire/ -- Pony.ai (NASDAQ:PONY), a global leader in autonomous driving technology, is ramping up its Robotaxi mass production and...

XCMG Champions “Solid Innovation for Green Tomorrow” at the 7th International Customer Festival

XUZHOU, China, June 6, 2025 /PRNewswire/ -- Xuzhou Construction Machinery Group Co., Ltd. - On May 20, the 7th XCMG International Customer Festival (hereinafter...

Fashion Walk x ADAHK Present: “CHEER Creative Art Week”

Two Murals by Artists with Disabilities Brighten Up Food Street @ Fashion WalkInteractive Workshops and Sharing Sessions Explore the Boundless Possibilities of Creativity Exclusive "CHEER-TOMATO"...

Delta Collaborates with the Jane Goodall Institute and NMMST to Expand Coral Restoration Education

TAIPEI, June 6, 2025 /PRNewswire/ -- The Delta Electronics Foundation announced a new collaboration with the Jane Goodall Institute and the National Museum of...

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA).

HIMSS Unites Global Healthcare Leaders to Shape the Future of Care: From Paris to Kuala Lumpur to Las Vegas

ROTTERDAM, Netherlands, June 6, 2025 /PRNewswire/ -- Thousands of health and technology leaders will gather to share critical health technology insights to optimize care...

iQIYI pioneers digital asset commercialization, leading the charge in scalable virtual production

BEIJING, June 6, 2025 /PRNewswire/ -- iQIYI, China's leading online entertainment platform, recently partnered with premier 3D digital asset trading platform CGModel.com to exclusively license...

Kelun-Biotech Announces Approximately US$250 Million Placement

CHENGDU, China, June 5, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of...

Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market

KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCollaboration

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers